Eribulin Makes 3: Changing Treatment Landscape for SarcomaEribulin Makes 3: Changing Treatment Landscape for Sarcoma
After a 40-year dearth of new treatments, three new drugs have been approved for soft-tissue sarcomas. Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - February 17, 2016 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news
FDA Approves Halaven (Eribulin) for Liposarcoma
By Stacy SimonThe US Food and Drug Administration (FDA) has approved the chemotherapy drug Halaven (eribulin) to treat liposarcoma, a type of soft tissue sarcoma. Halaven is already approved to treat advanced breast cancer. The new use is for people with liposarcoma who have already been treated with anthracycline-based chemotherapy and have tumors that cannot be removed through surgery or have spread to other parts of the body. This is the first drug approved for people with liposarcoma that has shown improvement in overall survival.Liposarcomas are cancerous tumors of fat tissue. They can develop anywhere in the body, bu...
Source: American Cancer Society :: News and Features - January 30, 2016 Category: Cancer & Oncology Tags: Sarcoma - Adult Soft Tissue Cancer Source Type: news
FDA Approves Halaven (eribulin mesylate) for the Treatment of Liposarcoma
January 28, 2016 -- The U.S. Food and Drug Administration today approved Halaven (eribulin mesylate), a type of chemotherapy, for the treatment of liposarcoma (a specific type of soft tissue sarcoma) that cannot be removed by surgery (unresectable)... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - January 28, 2016 Category: Drugs & Pharmacology Source Type: news
FDA approves first drug to show survival benefit in liposarcoma
The U.S. Food and Drug Administration today approved Halaven (eribulin mesylate), a type of chemotherapy, for the treatment of liposarcoma (a specific type of soft tissue sarcoma) that cannot be removed by surgery (unresectable) or is advanced (metastatic). This treatment is approved for patients who received prior chemotherapy that contained an anthracycline drug. (Source: Food and Drug Administration)
Source: Food and Drug Administration - January 28, 2016 Category: American Health Source Type: news
FDA approves first drug to show survival benefit in liposarcoma
The U.S. Food and Drug Administration today approved Halaven (eribulin mesylate), a type of chemotherapy, for the treatment of liposarcoma (a specific type of soft tissue sarcoma) that cannot be removed by surgery (unresectable) or is advanced (metastatic). (Source: World Pharma News)
Source: World Pharma News - January 28, 2016 Category: Pharmaceuticals Tags: Featured Food and Drug Administration (FDA) Regulatory Affairs Source Type: news
Early Trial Shows Injectable Agent Illuminates Cancer During Surgery
Contact: Samiha KhannaPhone: 919-419-5069Email: samiha.khanna@duke.eduhttps://www.dukemedicine.org
EMBARGOED FOR RELEASE until 2 p.m. (ET) Wednesday, Jan. 6, 2016
DURHAM, N.C. -- Doctors at Duke Medicine have tested a new injectable agent that causes cancer cells in a tumor to fluoresce, potentially increasing a surgeon’s ability to locate and remove all of a cancerous tumor on the first attempt. The imaging technology was developed through collaboration with scientists at Duke, the Massachusetts Institute of Technology (MIT) and Lumicell Inc.
According to findings published January 6 in Science Translational Medicine, a...
Source: DukeHealth.org: Duke Health Features - January 6, 2016 Category: Pediatrics Tags: Duke Medicine Source Type: news
Immune begins Phase II CMB305 trial to treat soft tissue sarcoma
Immune Design has started a Phase II trial of CMB305, a combination cancer immunotherapy for soft tissue sarcoma. (Source: Drug Development Technology)
Source: Drug Development Technology - November 12, 2015 Category: Pharmaceuticals Source Type: news
FDA clears J&J's chemotherapy for certain soft tissue sarcomas
(Reuters) - The U.S. Food and Drug Administration said it approved Johnson & Johnson's chemotherapy to treat specific soft-tissue sarcomas (STS) that have spread to other parts of the body or cannot be removed by surgery. (Source: Reuters: Health)
Source: Reuters: Health - October 23, 2015 Category: Consumer Health News Tags: healthNews Source Type: news
FDA Approves New Option for Soft-Tissue Sarcoma
(MedPage Today) -- Trabectedin slowed disease progression versus dacarbazine (Source: MedPage Today Public Health)
Source: MedPage Today Public Health - October 23, 2015 Category: American Health Source Type: news
FDA Approves Trabectedin for Two Soft Tissue SarcomasFDA Approves Trabectedin for Two Soft Tissue Sarcomas
Researchers saw no improvement in overall survival in the pivotal US trial, but there are explanations for that. FDA Approvals (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - October 23, 2015 Category: Consumer Health News Tags: Hematology-Oncology News Alert Source Type: news
New Drug Approved for Soft-Tissue Cancer
Disease most often affects head, neck, extremities and torso
Source: HealthDay
Related MedlinePlus Pages: Medicines, Soft Tissue Sarcoma (Source: MedlinePlus Health News)
Source: MedlinePlus Health News - October 23, 2015 Category: Consumer Health News Source Type: news
FDA approves new therapy for certain types of advanced soft tissue sarcoma
The U.S. Food and Drug Administration today approved Yondelis (trabectedin), a chemotherapy, for the treatment of specific soft tissue sarcomas (STS) – liposarcoma and leiomyosarcoma – that cannot be removed by surgery (unresectable) or is advanced (metastatic). This treatment is approved for patients who previously received chemotherapy that contained anthracycline. (Source: Food and Drug Administration)
Source: Food and Drug Administration - October 23, 2015 Category: American Health Source Type: news
YONDELIS® receives marketing approval in Japan for the treatment of STS
(Pharmamar) PharmaMar announced that its partner in Japan, Taiho Pharmaceutical, received marketing approval for YONDELIS® (trabectedin) by the Japanese Minister of Health, Labour and Welfare for the treatment of patients with soft tissue sarcoma. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - September 28, 2015 Category: Cancer & Oncology Source Type: news
PharmaMar shows new data for YONDELIS and PM1183 in soft tissue sarcoma and solid tumors at ECC 2015
(Pharmamar) PharmaMar showcases new data for anticancer compounds in soft tissue sarcoma and advanced solid tumors at the European Cancer Congress 2015 in Vienna. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - September 14, 2015 Category: Cancer & Oncology Source Type: news
Pazopanib improves progression-free survival without impairing quality of life
In patients with soft tissue sarcoma, whose disease had progressed during or after prior chemotherapy, pazopanib improved progression-free survival but did not change health-related quality of life, research shows. This observed improvement in progression-free survival without impairment of health-related quality of life was considered a meaningful result. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - July 6, 2015 Category: Science Source Type: news
